Austria’s health technology appraisal body, the Ludwig Boltzman Institut, has developed a new methodology for shedding light on how much public funding has been invested in the R&D for high-cost drugs. Better understanding of public contributions could lead to improved pricing policies, says the institute.
The new “investigational search strategy,” outlined in a project report, is one piece of a bigger puzzle on how to tackle unsustainable drug prices, said Claudia Wild, who heads the Ludwig Boltzman Institut